BAN2401 is one of a number of drugs that target beta amyloid, a protein that forms brain plaques that many believe are an underlying cause of Alzheimer’s. There are currently no treatments that can slow the progression of Alzheimer’s. Current drugs only ease some of the symptoms.
“This is really the first large study in which [plaque]reduction correlated with a reduction in cognitive decline,” Dr. Lynn Kramer, chief medical officer of Eisai, said, according to StatNews. “And that’s a very important correlation.”
For more information on the biotech sector, visit our biotechnology category.